CVRx, Inc. generates robust annual turnover through the commercial distribution of its Barostim neuromodulation therapy to hospital networks and specialized heart failure clinics in the United States and international markets like Germany. Official corporate financial reports filed with regulatory bodies indicate that the enterprise records annual revenues of approximately $56.7 million, reflecting a consistent double-digit growth trajectory driven by expanding physician adoption and wider insurance reimbursement coverage.